Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 7Gastrointestinal 6Genitourinary 3Thoracic 2Plasma cell 2Gynecologic 2Breast 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1CNS 1

Conditions

Multiple Myeloma 2

Interventions

Dexamethasone 479Lenalidomide 297Cyclophosphamide 271Bortezomib 267Melphalan 212Calcium Dobesilate 189fludarabine phosphate 121daratumumab 121Peripheral Blood Stem Cell Transplantation 101fludarabine 99carfilzomib 98Thalidomide 94pomalidomide 92Filgrastim 92Whole-Body Irradiation 88Mycophenolic Acid 88Busulfan 80Tacrolimus 75Granulocyte Colony-Stimulating Factor 72dexamethasone acetate 65ixazomib 62Cyclosporine 59dexamethasone 21-phosphate 56Antilymphocyte Serum 51auricularum 50isatuximab 44Radiotherapy 41Etoposide 40Stem Cell Transplantation 39Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × sonidegib × Plasma cell × Clear all
NCT02086552 2021-12-03

Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Mayo Clinic

Phase 2 Completed
28 enrolled 9 charts
Plasma cell

Multiple Myeloma

NCT02254551 2017-02-16

Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

SCRI Development Innovations, LLC

Phase 2 Terminated
7 enrolled 6 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡